FXR INHIBITION AS A NEW STRATEGY AGAINST COVID19

Teresa Brevini  ¹     Mailis Maes  ²     Gwilym J. Webb  ³     Claudia D. Fuchs  ⁴     Gustav Buescher  ⁵     Lu Wang  ⁶     Chelsea Griffiths  ⁶     Marnie Brown  ⁶     William E. Scott III  ⁶     Pehuén Pereyra Gerber  ⁶     William TH Gelson  ⁶     Daniele Muraro  ⁷     Jo Sharp  ⁸     Megan Neary  ⁸     Helen Box  ⁸     Lee Tatham  ⁸     James Stewart  ⁸     Sagar Varankar  ⁸     Mahnaz Darvish-Damavandi  ⁹     Rhoda E. Kuc  ¹⁰     Thomas L. Williams  ¹⁰     Thomas Marjot  ¹¹     Eleanor Barnes  ¹¹     Andrew M. Moon  ¹²     Sidney A. Barritt IV  ¹²     Ravindra K. Gupta  ¹²     Stephen Baker  ¹²     Anthony P. Davenport  ¹²     Gareth Corbett  ¹³     Simon JA Buczacki  ¹³     Joo-Hyeon Lee  ¹³     Nicholas J. Matheson  ¹³     Michael Trauner  ¹⁴     Andrew J. Fisher  ¹⁴     Paul Gibbs  ¹⁵     Andrew J Butler  ¹⁵     Christopher JE Watson  ¹⁵     George Mells  ¹⁵     Gordon Dougan  ¹⁵     Andrew Owen  ¹⁵     Ansgar W. Lohse  ¹⁶     Ludovic Vallier  ¹⁷     Fotios Sampaziotis  ^17    
1 Wellcome MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
² University of Cambridge, Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge
³ Cambridge Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
⁴ Hans Popper Laboratory of Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
⁵ University Medical Center Hamburg-Eppendorf, Hamburg, Germany
⁶ Transplant and Regenerative Medicine Laboratory, Translational and Clinical Research 11 Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
⁷ Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, Cambridge, United Kingdom
⁸ Centre of Excellence in Long-Acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom
⁹ Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
¹⁰ Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, United Kingdom
¹¹ Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, United Kingdom
¹² Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, United States
¹³ Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom
¹⁴ Head of Division of Gastroenterology and Hepatology - Department of Medicine III, Wien, Austria
¹⁵ Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
¹⁶ University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
¹⁷ Wellcome Trust Sanger Institute, Cambridge, United Kingdom

Session
Covid-19 in GI (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)